Huons Announces Poster Presentation on Preclinical Results of 'Fibrostenotic Crohn’s Disease Treatment' at the UEG Week 2026

Confirmed that inhibition of TG2 suppresses ECM cross-linking and intestinal fibrosis [Press Release] Huons has disclosed preclinical research results of its Crohn’s disease drug candidate at an international congress. Huons (CEO Song Soo-young) announced on the 20th that it presented preclinical research results for 'HUC1A-626', a selective TG2 inhibitor, via a poster presentation at the annual congress of the 'UEG Week 2026' (United European Gastroenterology Week 2026), held in Barcelona, Spain, from October 17th to 20th (local time). 'HUC1A-626' is a candidate molecule current

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand [Press Release] Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership. Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with th

LOTTE Biologics to Unveil 'Songdo Era' at BIO International 2026 Ahead of Plant 1 Completion

Showcasing its Syracuse-Songdo dual network to accelerate globl CDMO market expansion. [Press Release] LOTTE Biologics announced on June 4 that it will be participating in the BIO International Convention 2026, taking place this month in San Diego, California. Hosted annually by the Biotechnology Innovation Organization (BIO), BIO International Convention is one of the world's largest biotechnology events, bringing together global biopharmaceutical companies and industry stakeholders, with LOTTE Biologics marking its fifth consecutive year of participation since its launch in 2022

LOTTE BIOLOGICS Hosts Technology Development Forum to Foster Future Innovation

Photo=LOTTE BIOLOGICS [Press Release] LOTTE BIOLOGICS announced on December 12th that it held the "Future Innovation Technology Development Forum" for employees at the multipurpose hall of the IBS Tower in Songdo. Since last year, the company has been regularly hosting this forum, which focuses on the latest biopharmaceutical development and manufacturing technologies, in order to strengthen technological differentiation and collaboration in the global market. It also serves as a platform for kn

Hanmi Highlights Next-Generation Obesity Pipelines at ObesityWeek 2025

Presentations Feature First-in-Class CRFR2-Selective HM17321 and Best-in-Class Triple Agonist HM15275 Researchers from Hanmi’s R&D and Clinical Teams explain study findings on HM17321 and HM15275 to attendees at ObesityWeek 2025 [Press Release] Hanmi Pharmaceutical announced on November 10, Hanmi Pharmaceutical presented new research at ObesityWeek 2025 for its next-generation obesity drug candidates designed to achieve both weight reduction and muscle growth. With presentations for the second consecutive year at the largest pharmaceutical market in the world, Hanmi further strengthened recognit

SK bioscience Earns 'A' Rating in KCGS ESG Assessment for Fourth Consecutive Year

Achieves "A (Excellent)" rating for the fourth year, reaffirming maturity of ESG management [Press Release] SK bioscience has once again demonstrated its leadership in ESG management within Korea’s pharmaceutical and biotechnology sector. The company announced on the 19th that it received an integrated A rating in the 2025 ESG assessment conducted by the Korea Institute of Corporate Governance and Sustainability (KCGS). SK bioscience has maintained the same grade for four consecutive years since it first earned an A rating in 2022, underscoring the company’s recognized capabilities and

Huons N to Acquire Health Functional Food Manufacturer 'Biorosette'

Expanding global presence with manufacturing competitiveness [Press Release] Huons N, a lifecare solutions company under Huons Group, is strengthening its manufacturing capabilities by acquiring a health functional food (HFF) manufacturer Biorosette Co., Ltd. Huons N has announced on November 17 that the company has acquired 250 thousand shares in Biorosette, incorporating it as a wholly-owned subsidiary. Through this acquisition, Huons N plans to leverage its existing value chainㅡfrom raw material research and development to manufacturing and export—to r

European Commission Grants Approval of Remsima IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab

The approval is based on the comparability data between infliximab powder formulation and the liquid formulation [Press Release] Celltrion announced on November 18, the European Commission (EC) has granted marketing authorization for Remsima IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency. The Remsima IV liquid formulation is approved in the EU for all indications of IV inflixim

Celltrion receives U.S. FDA approval for EYDENZELT, biosimilar referencing EYLEA

Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions [Press Release] Celltrion announced on October 9 that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT (aflibercept-boav), biosimilar referencing EYLEA (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR). Aflibercept is a VEGF inhibitor formulated as an injection for the eye that blocks the growth of new blood vessels and de

FDA approves expanded pediatric indications for YUFLYMA and unbranded adalimumab-aaty in the United States

[Press Release] Celltrion announced on October 17 that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in pediatric patients aged 2 years and older. The FDA previously approved YUFLYMA as a biosimilar to Humira for a variety of indications, including rheumatoid arthritis (RA), psoriatic ar